Fang Nan

Dr. Fang Nan is the Chairwoman, CEO and co-founder of Singleron Biotechnologies, a molecular diagnostic enterprise that offers innovative single cell sequencing technology services. Based in China, the company was founded in 2018 and launched its single cell assay kit in 2019. 

Singleron has completed the development and commercialization of a globally acclaimed single cell sequencing platform. This has facilitated the launch of five distinctive product lines, encompassing nearly 40 products catering to various single cell sequencing applications. 

Dr. Fang Nan has over 10 years of experience in product development, commercialization, team management, and corporate strategy in world-leading biotechnology companies in Germany, US, and China. Before co-founding Singleron, Dr. Fang was Deputy General Manager at Novogene and responsible for development of novel NGS service solutions. Prior to Novogene, she was Associate Director of Global R&D at QIAGEN, Germany, founding and leading the product development team of the Universal NGS Market Program. Dr. Fang was a member of Life Sciences Business Area Management Committee at QIAGEN and directly participated in the decision-making process in the Business Area. At QIAGEN and Novogene, Dr. Fang and her team launched more than 30 products. She is inventor on over 20 patents and patent applications.

Dr. Fang has been awarded multiple prizes, including “Forbes China Top 50 Women in Tech 2020”; “Jiangsu Province Entrepreneur of the Year 2019”; “one of 100 Leading Female Entrepreneurs in Nanjing”; “Nanjing Entrepreneurship Award”; “Technology Leadership of Suzhou BioBay”; “Technology Leadership of Suzhou City”; and “Innovation and Entrepreneurship Award of Jiangsu Province”. She believes innovative shifts in basic and clinical research, along with the pharmaceutical industry, can be catalyzed by advanced technologies, such as single cell sequencing and analysis.